ANGO

AI MemoPost-earnings T+3

AngioDynamics

As of 2026-10-13/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-13 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

FY2027 guidance faces a post-earnings credibility test • 2027-05-31

Base target: $13 / p=45% prob

Biggest risk

Guidance was only reiterated, GAAP loss remained $7.1 million, cash declined after a $15.3 million quarterly operating outflow, and part of the reported margin benefited from tariff refunds. The roughly 20% decline from the pre-earnings close suggests investors demand more proof of sustainable profitability; that interpretation is an inference, not a stated company explanation. SEC earnings exhibit company stock history

Invalidation

Break below $8 or thesis failure.

What would change my mind?

Med Tech revenue grew 13.2%, led by Auryon, AlphaVac and NanoKnife, while adjusted EBITDA rose to $5.0 million from $2.2 million. If growth, reimbursement-driven utilization and cash conversion persist, the post-print selloff may prove excessive [#SEC-8K-2026-10-08].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-13

Base target

$13

p=45%

Bull target

$17

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Cash conversion and margin normalization risk
NanoKnife utilization and reimbursement adoption
Med Tech revenue grew 13.2%, led by Auryon, AlphaVac and NanoKnife, while adjusted EBITDA rose to $5.0 million from $2.2 million.

BearKey bullets

Eric Honroth is due to succeed Jim Clemmer as CEO on November 2, creating transition execution risk [#SEC-8K-2026-10-08].
FY2027 guidance was reiterated rather than raised, and Med Device sales grew only 1.4% in Q1 [#SEC-8K-2026-10-08].
Gross margin benefited from tariff refunds; management expects second-half FY2027 margin below first-half margin [#SEC-8K-2026-10-08].

WatchKey bullets

FY2027 guidance faces a post-earnings credibility test

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $13 (p=45%)

Target spread vs base: +31% / -38%

Scenario probabilities

Bull Target: $17 (p=25%)Base Target: $13 (p=45%)Bear Target: $8 (p=30%)

Commentary

The stock fell from $14.19 on October 7 to $11.23 on earnings day, then closed October 12 at the packet’s $11.40 anchor—about 19.7% below the pre-release close. The reaction has not materially reversed despite a narrower adjusted loss and Med Tech growth. One reported post-print Canaccord Buy/$20 reiteration is not evidence of broad upward revisions; forward-estimate changes were unavailable. Social, options, short-interest and employee measures were not supplied; zeros above mean unavailable, not neutral. company stock history

As of 2026-10-13 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Cash conversion and margin normalization risk
NanoKnife utilization and reimbursement adoption

Scenarios

Bull Target (Scenario probability)

$17 / p=25% prob

Base Target (Scenario probability)

$13 / p=45% prob

Bear Target (Scenario probability)

$8 / p=30% prob

Analysis 2026-10-13 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

-0.30

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-05-31
FY2027 guidance faces a post-earnings credibility test
Fiscal Q1 sales rose 6.9% to $80.9 million and adjusted loss narrowed to $0.04 per share, but management reiterated rather than raised FY2027 sales guidance of $336 million–$341 million and adjusted EBITDA guidance of $13 million–$16 million. Sustaining the guided 12%–15% Med Tech growth is the key test after the sharp share-price decline [#SEC-8K-2026-10-08]. SEC earnings exhibit
Prob 55.00% • Move 14.00% • Priced-in 35.00%
EVENT2027-05-31
RELIEF feasibility-study progress
The FDA approved an investigational-device exemption for a 40-subject, up-to-five-site study of NanoKnife for benign prostatic hyperplasia, with a six-month symptom-score endpoint. Enrollment progress could clarify the opportunity, but no readout date was disclosed; the date shown is a monitoring horizon, not a company milestone [#SEC-8K-2026-10-08]. SEC earnings exhibit
Prob 45.00% • Move 12.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Cash conversion and margin normalization risk
2027-05-31
Q1 operating cash outflow was $15.3 million, leaving $34.0 million of cash and no debt. Gross margin of 59.4% included tariff refunds; excluding them, it was 57.8%, and management expects a lower margin in the second half. Failure to convert Med Tech growth into cash generation could extend the selloff [#SEC-8K-2026-10-08]. SEC earnings exhibit
Prob 45% • Move -22% • Priced-in 55%

Long-term Catalysts

Months to a year

NanoKnife utilization and reimbursement adoption
2027-05-31
Q1 NanoKnife sales rose 29%, including 24.1% probe growth. Medicare coverage for qualifying prostate- and liver-cancer procedures became effective July 5; sustained procedure and probe growth would provide stronger evidence that coverage is translating into adoption [#SEC-8K-2026-10-08] [#SEC-8K-2026-07-14]. Q1 exhibit
Prob 55% • Move 20% • Priced-in 40%

Risks

Eric Honroth is due to succeed Jim Clemmer as CEO on November 2, creating transition execution risk [#SEC-8K-2026-10-08].
FY2027 guidance was reiterated rather than raised, and Med Device sales grew only 1.4% in Q1 [#SEC-8K-2026-10-08].
Gross margin benefited from tariff refunds; management expects second-half FY2027 margin below first-half margin [#SEC-8K-2026-10-08].
Q1 operating cash outflow of $15.3 million against $34.0 million quarter-end cash, despite a debt-free balance sheet [#SEC-8K-2026-10-08].
RELIEF remains a feasibility study; enrollment, outcomes, durability and any larger clinical program are uncertain [#SEC-8K-2026-10-08].

Peers

Symbol	Summary
BSX	Relevant cardiovascular-device benchmark, but substantially larger and more diversified; not a direct small-cap valuation peer.
MMSI	Vascular-intervention and access-device comparator, though its portfolio differs from AngioDynamics’ NanoKnife and atherectomy mix. Merit product overview
PEN	Directer mechanical-thrombectomy product comparator: Penumbra markets peripheral and pulmonary-embolism clot-removal systems. Its broader business and scale limit valuation comparability. Penumbra product page

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-13

Loading AI feed…

Symbol

Summary

BSX

Relevant cardiovascular-device benchmark, but substantially larger and more diversified; not a direct small-cap valuation peer.

MMSI

Vascular-intervention and access-device comparator, though its portfolio differs from AngioDynamics’ NanoKnife and atherectomy mix. Merit product overview

PEN

Directer mechanical-thrombectomy product comparator: Penumbra markets peripheral and pulmonary-embolism clot-removal systems. Its broader business and scale limit valuation comparability. Penumbra product page